Natural Capsules Limited has received relief from the Madras High Court, which has suspended the Drug Controller's order for temporary closure of the company's manufacturing plant in Pondicherry. The pharmaceutical company announced the resumption of operations following the court's intervention in the regulatory matter.

Court Order Details

The Madras High Court issued an order suspending the suspension directive previously passed by the Department of Drug Controller. Natural Capsules Limited received the court order on January 29, 2026, enabling immediate resumption of manufacturing activities at its Pondicherry facility.

Regulatory Violation Background

The temporary closure was initiated due to a regulatory compliance issue involving material supply to a customer whose drug license had expired. This violation led to the Drug Controller's Department taking action against the company's manufacturing operations.

Financial Impact Assessment

The temporary closure of the Pondicherry manufacturing plant had measurable financial consequences for Natural Capsules Limited. The company quantified the operational disruption's impact on its business performance.

Compliance and Disclosure

Natural Capsules Limited has fulfilled its regulatory disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company previously informed exchanges about the initial closure on December 26, 2025, and has now updated stakeholders regarding the court's favorable decision.

The resumption of operations at the Pondicherry facility allows Natural Capsules Limited to restore its full manufacturing capacity and work toward recovering the sales impact experienced during the temporary shutdown period.

Natural Capsules Limited , a prominent player in the pharmaceutical industry, has made significant announcements regarding leadership changes and developments at its material subsidiary that reflect evolving corporate dynamics.

Rights Issue Cancellation by Material Subsidiary

In a significant development, Natural Biogenex Private Limited, the material subsidiary of Natural Capsules Limited, has decided not to proceed with its previously approved rights issue. The Board of Directors of Natural Biogenex Private Limited made this decision in their meeting held on January 03, 2026, citing non-subscription by the major shareholder as the primary reason.

The cancelled rights issue details were as follows:

This decision was communicated to the stock exchanges under Regulation 30(9) of SEBI (LODR) Regulations, 2015, with reference to the company's earlier intimation dated September 30, 2025, when the rights issue was initially approved.

Chief Operating Officer Retirement

Natural Capsules Limited has also disclosed the upcoming retirement of Mr. MVN Kutty, the company's Chief Operating Officer (COO). The retirement is due to superannuation and will be effective from the close of business hours on September 30, 2025.

Regulatory Compliance and Communication

Both announcements were made by Pranjal Deshmukh, the Company Secretary & Compliance Officer of Natural Capsules Limited, ensuring full compliance with regulatory requirements. The cancellation of the rights issue represents a notable shift from the subsidiary's earlier capital raising plans, potentially impacting the group's expansion and investment strategies.

The decision not to proceed with the rights issue due to lack of support from the major shareholder highlights the importance of stakeholder alignment in corporate financing decisions. This development may require Natural Biogenex Private Limited to explore alternative funding mechanisms for its growth initiatives.